Business Wire

Alter Domus Strengthens its Competitive Differentiation with Continued Investments in European Operational Excellence

25.11.2021 10:00:00 EET | Business Wire | Press release

Share

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, is enhancing its European service offering by making substantial investments in its central operations.

The initiative is focused on building additional technology capability, expanding its European footprint, and continuing to recruit exceptional, multilingual talent to support Alter Domus in providing corporate and fund services to investors and managers in private equity, real assets, and debt capital markets.

Launching an Ambitious Digital Agenda

At the core of its €50 million investment is technology. Alter Domus is pursuing an ambitious digital agenda in software development, network and infrastructure, security and systems engineering, and quality assurance.

This complements the rollout of new client-facing technology, CorPro, digitalising investors’ and managers’ traditional workflows to significantly improve access to data and achieve efficiencies across different geographies, funds, and product types.

This in-house technology was enhanced with the acquisition of London-based SaaS platform, Credit-Vision, whose solution for corporate credit investors was vertically integrated into Alter Domus’ technology stack during 2021.

Scaling via European footprint

In addition to expanding its Irish operations in 2021, Alter Domus opened its doors in Lithuania and now benefits from operations centres in Cork, Vilnius, and Malta to house central operations as well as functions including technology and HR. In Ireland and Lithuania alone, Alter Domus has hired more than 200 new employees in 2021. Luxembourg continues to play a critical role in knowledge sharing to Alter Domus’ new operations centres as it remains a leading European centre of excellence.

Exceptional, Specialised Talent

Across Europe, Alter Domus plans to hire an additional 270 technology, accounting, legal, compliance and tax specialists in Luxembourg, Cork, and Vilnius in 2022, to scale across the continent.

This will support Alter Domus in capturing the growing demand for incremental outsourcing as global alternatives investment managers in North America and Asia – who have an estimated $2.5 trillioni in dry powder to deploy – increasingly look to Europe to launch and manage new funds.

Alter Domus has fully deployed a hybrid working model and benefited from a greater appetite amongst exceptional talent to switch functional roles since the beginning of the pandemic. Those alternatives specialists seeking to switch are demanding a more technology-centric role without losing their sector expertise.

Through a proprietary training program, The acADemy, Alter Domus employees are enhancing their technical, professional and leadership skills. 1,800 Alter Domus employees in 13 European locations have already benefited from The acADemy, amounting to over 30,000 hours of training delivery.

Sandra Legrand, Regional Executive for Europe at Alter Domus, said: “In a year when Alter Domus has topped $1 trillion in assets under administration, we have in place the strongest technological capabilities and expanded our talented central operations team to support our clients and the rising complexity of their assets.”

“Our technology investment programme is strengthening our ability to help alternatives investors and managers grapple with a data deluge. Our technology is optimising managers fund and portfolio performance when they’re raising, managing, and deploying funds, and reporting this all back to their end-investors to overcome the intricate web of regulatory and compliance requirements.”

Heather Crowley- Kerr, Head of Central Operations Europe at Alter Domus, said: “Fund administration is a people industry increasingly defined by digital transformation. Whilst we’re automating our processes to serve our clients more efficiently, we’ve more than doubled our workforce in central operations since 2016 to maintain our hybrid operating model which blends human with digital.”

“Through an internal knowledge transfer system, we’ve exported some deep technical knowledge and experience that sits within Luxembourg and Malta to two additional hubs in Cork and Vilnius which now employ over 350 people. In the last year, we’re proud to have trained over 175 employees in the entire alternatives product lifecycle, so we retain our competitive advantage in being the only fund services and asset administration provider solely dedicated to providing superior expertise to private equity, credit, real estate and infrastructure investors and managers.

We look forward to our continued growth within our central operations and to welcoming additional talent to join us on the Alter Domus journey.”

# #

ABOUT ALTER DOMUS

Alter Domus is a leading provider of fund administration, debt capital markets and corporate services for the alternative investment industry. Through vertical integration, dedicated teams provide support and bespoke solutions across entire value chains. By tapping into a talent pool of more than 3,300 employees across 36 offices in 21 jurisdictions, our expertise and cutting-edge technology combine to put clients ahead of the game.

With an established professional focus on private equity, venture capital, real estate, infrastructure, and credit sectors, we offer fund administration, debt capital markets services, corporate services, depositary services, capital administration, transfer pricing, domiciliation and management company services. Our specific experience in the debt capital markets sector allows us to provide specialist solutions such as loan administration, agency services, trade settlement and CLO manager services.

Alter Domus proudly serves 16 of the 20 largest private equity houses, 17 of the 20 largest real estate firms, and 17 of the 20 largest private debt managers in the world. For more information, please visit: www.alterDomus.com.


i Source: Preqin (as at November 2021) North America = $1.778 Tn and APAC = $0.762 Tn of dry powder

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Patrick Gritti
Global Head of Marketing and Communications, Alter Domus
+352 48 18 28 3835
+352 661 112 515
patrick.gritti@alterdomus.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 08:00:00 EEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 05:00:00 EEST | Press release

Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated over the three years through 2028. The amount to be awarded to Helical Fusion will be announced following the formal grant

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28 [1]1.9.2026 00:35:00 EEST | Press release

ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will synergistically blend ITCI’s AI-led capabilities across Cloud, Data Analytics, PLM, SAP, enterprise transformation, industry-spe

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 22:07:00 EEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye